Long-term results of the Medtronic Mosaic porcine bioprosthesis in the aortic position  by Anselmi, Amedeo et al.
A
C
D
Acquired Cardiovascular Disease Anselmi et alLong-term results of the Medtronic Mosaic porcine bioprosthesis
in the aortic positionAmedeo Anselmi, MD, Erwan Flecher, MD, PhD, Vito Giovanni Ruggieri, MD, PhD,
Majid Harmouche, MD, Thierry Langanay, MD, Herve Corbineau, MD,
Jean-Philippe Verhoye, MD, PhD, and Alain Leguerrier, MDFrom th
Hosp
Disclosu
Receive
public
Address
Surge
Franc
0022-52
Copyrig
http://dx
1884Objective:We addressed the long-term results of theMedtronicMosaic porcine prosthesis in the aortic position.
Methods: From 1994 to 2004, 1007 Mosaic valves were used for aortic valve replacement. The data were
prospectively collected, retrospectively analyzed, and stratified according to patient age at surgery (group 1,
<70 years; group 2, 70-75 years; group 3, 76-80 years; and group 4,>80 years), using both actual (cumulative
risks) and actuarial methods.
Results: Operative mortality was 5% (valve related in 14%). Globally, 8122.17 patient-years were available
(average follow-up, 8.5 3.9 years; 99.8% complete). Overall, survival at 15 years was lower among the elderly
strata (P<.0001). Freedom from structural valve deterioration (SVD) was 95.1% (actual) and 86.3% (actuarial;
24 SVD events). Survival free from SVD was lower in group 1 (P ¼ .003) but comparable among the other
groups. Overall freedom at 15 years from the composite endpoint (any valve-related adverse events) was
82% (actual) and 71.3% (actuarial). No meaningful intergroup differences were found in survival free from
the composite endpoint (P ¼ .9) or freedom from valve-related mortality (P ¼ .8). Younger patients at surgery
did not show accelerated degeneration. No relationship could be established between prosthetic size and SVD.
Conclusions: The implantation of a bioprosthesis in patients aged 70 years or older remains fully justified. The
rate of SVD was higher in younger patients, mainly owing to their greater life expectancy. Patients younger than
70 can receive a bioprosthesis, provided that the correct information regarding the expected durability has been
provided. This might be better accomplished through the actual methodology. (J Thorac Cardiovasc Surg
2014;147:1884-91)Third-generation bioprostheses for aortic valve replace-
ment are now attaining the long-term follow-up data that
allow consistent evaluation of durability. The Mosaic
porcine valve (Medtronic Inc, Minneapolis, Minn) was
introduced in 1994. It has been the object of a multi-
institutional regulatory study, which established its favor-
able profile in terms of safety, thromboembolic event rate,
and hemodynamic performance.1-4 The same surgical
groups have recently reported on the 12-year performance
of this device, including freedom from late valve-related
adverse events in 797 patients who had undergone aortic
valve replacement and 232 patients who had undergone
mitral valve replacement.5 Although reporting most satis-
factory freedom from structural valve deterioration (SVD)
rates, these investigators underlined the need for continuede Division of Thoracic and Cardiovascular Surgery, Pontchaillou University
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The Journal of Thoracic and Cardiovascular Surevaluation at longer follow-up intervals. In particular,
additional insights are needed regarding the effects of
patient age at surgery on the incidence and timing of
valve-related adverse events.
The objective of the present investigation was twofold.
We aimed to assess the long-term clinical results of the
Mosaic prosthesis in a large single-institution series and
to clarify the expected rates of SVD and other valve-
related adverse events according to patient age at surgery.
Our ultimate purpose was to offer useful information for
preoperative decision making. Therefore, we analyzed the
outcome variables using both the actual method (which
provides the real incidence of valve-related complications
by eliminating the censoring from competing risks) and
the actuarial analysis.METHODS
Inclusion Criteria and Management of Data
We retrospectively reviewed the electronic records of 1005 patients who
had received at our institution a total of 1007 Medtronic Mosaic porcine
bioprostheses from July 31, 1994, to August 1, 2004. We included all
patients who had undergone aortic valve replacement using a Mosaic valve
in the aortic position during the study period. The performance of any
associated cardiac surgical procedure at implantation, in terms of a history
of previous cardiac surgery, did not represent exclusion criteria. The
perioperative clinical data were prospectively collected, as previously
described.6 In brief, the baseline variables, intraoperative findings, andgery c June 2014
Abbreviations and Acronyms
IE ¼ infective endocarditis
NSVD ¼ nonstructural valve dysfunction
SVD ¼ structural valve deterioration
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Dearly postoperative results for all patients undergoing cardiac surgery at the
Rennes University Hospital are systematically entered in an electronic
database at patient discharge. The database is regularly checked for
completeness and consistency. Clinical follow-up data were collected in
late 2012 by contacting the referring cardiologist of each patient. The
practitioners were provided a questionnaire that included inquiries of the
patient’s status (occurrence of death or any other adverse event, valve
related or non–valve related) and the time at which the adverse event had
occurred. In the event of missing or incomplete information, the general
practitioners or the patients themselves were interviewed by telephone.
The definitions of valve-related events were established in compliance
with the current recommendations.7 SVD was defined as dysfunction or
deterioration of the prosthesis (excluding infection or thrombosis) evident
on echocardiography and/or at reoperation. The cause of death was
determined by review of the instrumental and hospital records. Any death
from unknown causes was entered into subsequent analyses as a valve-
related lethal event. Similarly, mortality resulting from adverse cerebrovas-
cular events was assumed to be valve related. Operative mortality was
defined as death within 30 days of surgery. Nonstructural valve dysfunction
(NSVD) included any abnormality not intrinsic to the valve itself that
resulted in stenosis or regurgitation of the bioprosthesis or hemolysis.
Any infection involving the prosthesis was considered infective endocardi-
tis (IE). All patients underwent echocardiography before discharge, at the
first postoperative months, and later on a regular basis according to territo-
rial hospital and practitioner preference. Unscheduled echocardiography
was performed in the case of new symptoms or unexplained fever. The
preoperative logistic EuroSCORE I was calculated for each patient using
the prospectively collected data and the algorithm available online
(www.euroscore.org). Two patients underwent repeat surgery during the
follow-up period before of prosthetic endocarditis and had a new Mosaic
valve implanted. For the purpose of the time-to-event analysis, for these
patients, the reoperation was considered as the last event attributable to
the originally implanted prosthesis. Both patients were re-entered in the
follow-up analysis for the new implanted prostheses. Individual patient
consent to enter the study was waived, because all data were treated
retrospectively and anonymously. Additionally, the present data set was
registered within the CLIN online database (Commission Nationale de
l’Informatique et des Libertes [National Committee for Informatics and
Freedom]) under the dossier number 1207754, in accordance with
French law.
No major changes were introduced in our surgical or anesthesiology
protocols during the inclusion period. The aortic valve was accessed in
all cases by full median sternotomy, complete cardiopulmonary bypass,
and cardioplegic arrest. All bioprostheses were implanted using U-shaped,
interrupted sutures in a supra-annular configuration. Postoperative man-
agement included lifelong treatment with lysine acetylsalicylate, 160
mg/d. No oral anticoagulant treatment was given in the early postoperative
months, otherwise indicated on the basis of coexisting clinical conditions
(ie, atrial fibrillation).
Endpoints
The first study endpoints were overall survival and freedom from SVD
at long-term follow-up for patients who received the Medtronic Mosaic
porcine valve in the aortic position. The third endpoint was survival free
from valve-related adverse events (composite endpoint that included
valve-related mortality, SVD, NSVD, IE, and thromboembolic andThe Journal of Thoracic and Carhemorrhagic events). To clarify whether the occurrence of valve-related
adverse events (ie, SVD) was age-dependent, the analyses were stratified
according to patient age at surgery: group 1, younger than 70 years; group
2, 70 to 75 years; group 3, 76 to 80 years; and group 4, older than 80 years.
The fourth endpoint was the identification of risk factors for the occurrence
of SVD during the follow-up period.
Statistical Analysis
Statistical Analysis Systems software, version 9.33 (SAS Institute Inc,
Cary, NC), was used for data storage and analysis. Continuous variables
are reported as the mean  standard deviation and categorical variables
as percentages. An intergroup comparison was conducted using the chi-
square test and Fisher’s exact test for categorical and continuous variables,
respectively. For the time-to-event analysis, both the actuarial (Kaplan-Me-
ier) and the actual (cumulative risks) methods were used.8 The analyses
were eventually stratified by age group. Opposite Kaplan-Meier curves
for the survival estimates were compared using the log-rank statistic. For
the purposes of the Kaplan-Meier curves, operative deaths were excluded,
and only deaths during the follow-up period were considered. We built a
Cox proportional hazards regression model to identify potential predictors
of SVD occurrence during the follow-up period. After univariate analysis,
all variables attaining an a level of 0.02 were entered in the model as
explanatory variables. The assumptions of Cox regression were checked
and met, and the model was tested. A diagnostic performance analysis
for the logistic EuroSCORE I in predicting operative mortality was per-
formed by construction of the applicable receiver operating characteristic
curve, and the area subtending such a curve was quantified as a measure
of discrimination (area under the curve). The a level was 0.05.RESULTS
In the overall population, the average age was 74.7  6.8
years (median, 75; range, 26-93), 63% of the patients were
men, and 41.9%were hospitalized while in New York Heart
Association functional class III or IV. Aortic stenosis was the
prevalent indication for valve replacement surgery, because
aortic regurgitation of 3 to 4 or greater was present in 5.8%
of cases. The average preoperative maximum and mean
transvalvular gradient was 83.4  21.6 mm Hg and 52.2 
15.5 mm Hg, respectively. The average left ventricular
ejection fraction was 59%  12.1%. The operative timing
was nonelective in 2.1% of the patients, and redo surgery
was performed in 3.2% of cases after an average 13.3 
6.1-year interval after primary surgery (previous operations
were coronary bypass surgery in 1.8%, aortic valve replace-
ment in 1.3%, and mitral valve replacement in 0.1%).
Among the patientswhounderwent redo aortic valve replace-
ment at the index reoperation, the indications were SVD of a
previous bioprosthesis (0.8%), valve thrombosis (0.1%), and
IE (0.4%), with the Medtronic Mosaic valve involved in 2
cases of IE. Associated procedures were performed in
19.9% of operations (concomitant coronary bypass in
14.6%, ascending aortic replacement in 3.4%, and other
procedures in 1.9%, including a 1.1% rate of concomitant
mitral replacement or repair). The nominal diameter of the
implanted valve was 19 mm in 4.8% of patients, 21 mm in
28.4%, 23 mm in 44.2%, 25 mm in 19%, and 27 mm in
3.7%. Group 1 included 9.9% of the overall population;
group 2, 35.2%; group 3, 35.8%; and group 4, 19.1%.diovascular Surgery c Volume 147, Number 6 1885
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14% of cases (n ¼ 7). According to the current recommen-
dations, the valve-related causes of death included stroke in
4 patients, an undetermined cause in 1, and noncerebral
(pulmonary) embolism in 2. The leading non–valve-
related causes of death were abdominal complications
(26%, including peritonitis and mesenteric infarction
whose embolic origin was not documented), heart failure
in patients with advanced myocardial disease and well-
functioning valves (16%), multiorgan failure (14%), and
myocardial infarction (14%). Five valve-related nonlethal
adverse events (4 cases of prosthetic thrombosis and 1
case of prosthetic endocarditis) occurred. The average
logistic EuroSCORE I was 8.6%  7.8%, which globally
overestimated the observed mortality. The corresponding
receiver operating characteristic area under the curve was
0.7903, indicating adequate, but not optimal, discrimination
of this prediction model in our series of aortic valve replace-
ment operations (curve not shown).
The study design is given in Figure 1. Two patients were
lost to follow-up; therefore, we had a total of 955 patients
and 8122.17 patient-years available for analysis. The
average follow-up period was 8.5  3.9 years (longest
follow-up, 18.1). At the end of the follow-up period, 583
patients overall had died (61%). Death was valve related
in 8.8% (thromboembolic or hemorrhagic events in 19 pa-
tients, IE in 7, other adverse cerebrovascular events in 24,
and primary valve dysfunction in 1 patient only). Death
was cardiac in origin in 25.8% of patients (including valve-
and non–valve-related causes). In the overall population, the
survival rate at 5, 10, and 15 postoperative years was 79.7%
 1.3%, 50.5% 1.7%, and 23.4% 2.2%, respectively.
As expected, the overall survival at 15 years was signifi-
cantly lower among the elderly patients at surgery, because
of their lower life expectancy: 47%  9.3% in group 1,
25.1%  3.8% in group 2, 21.7%  3.4% in group 3,
and 9%  3.9% in group 4 (P<.0001, Figure 2, A).FIGURE 1. Study design. See the text for details.
1886 The Journal of Thoracic and Cardiovascular SurDuring the follow-up period, 26 SVD events occurred in
24 patients, and the average interval between surgery and
the first SVD event was 9.3  4.9 years. The actuarial
freedom from SVD at 5, 10, and 15 years was 99.3% 
0.3%, 97.9%  0.6%, and 86.3%  3.9%, respectively.
In contrast, the actual method yielded the following corre-
sponding rates: 99.4%  0.3%, 98.5%  0.4%, and
95.1%  1.2%. The freedom from SVD stratified accord-
ing to age group is listed in Table 1. The actual method
described the number of SVD events that factually
occurred in the population, and, consequently, the risk to
individual patients of incurring an SVD at a given point.
The poorer actuarial rates reflected the burden of
competing events (death from non–SVD-related causes)
that censored the occurrence of SVD. Hence, the risk of
developing SVD at 15 years was 10.3% in patients
younger than 70 years, 2.9% in patients aged 70 to 75
years, 0.9% in patients aged 76 to 80 years, and 0.6%
in patients older than 80 years at implantation. The
survival free from SVD was similar among groups 2, 3,
and 4; however, the patients in group 1 displayed signifi-
cantly worse SVD-free survival (P ¼ .003, Figure 2, B).
Cox proportional hazards regression identified younger
age as the only independent predictor of the development
of SVD during the follow-up period (P ¼ .007). Among
the patients who developed SVD, 8 underwent repeat
surgery after 9.4 years (mortality rate at reoperation,
12%; average age at reoperation, 67.8 years). The
remainder did not undergo reoperation because of exces-
sive estimated surgical risk (8 patients), stable and moder-
ate valve dysfunction resulting from SVD (5 patients), or
other or unknown reasons (3 patients). Among the patients
who were refused reoperation because of excessive
surgical risk, the valve-in-valve procedure was discussed
for 4. Of these, 1 underwent valve-in-valve implantation,
2 cases were waived because of unsuitable anatomy and/
or unlikely clinical benefit, and 1 was waiting for the final
heart team decision. The echocardiographic findings of the
explanted SVD prostheses were prevalent stenosis in 3
cases, prevalent regurgitation in 1, and a mixed lesion in
4. Among the nonexplanted prostheses affected by SVD,
the findings were prevalent stenosis in 6 cases, mixed
lesions in 10, and prevalent regurgitation in none. The
pathologic assessment of the explanted bioprosthesis
indicated that the mechanism responsible for valve failure
was the association of leaflet calcification and tear in most
cases (50%), leaflet tear in 25%, and predominant calcifi-
cation of leaflet and commissures in the remaining 25%.
The overall freedom from reoperation for SVD at 5, 10,
and 15 years was 99.9%  0.1%, 9%  0.4%, and
95.5%  2.3% using the actuarial method and 99.9%
 0.1%, 99.4%  0.3%, and 98.4%  0.7% using the
actual method, respectively. The freedom from reoperation
for SVD according to the age cohorts is listed in Table 2.gery c June 2014
FIGURE 2. Kaplan-Meier curves for follow-up survival, stratified by age group (log-rankP values shown). A, Overall survival. B, Survival free from struc-
tural valve deterioration. C, Survival free from reoperation for structural valve deterioration. D, Survival free from the composite endpoint. SVD, Structural
valve deterioration.
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4 (100% freedom for both). Concordantly, the Kaplan-
Meier analysis indicated significantly worse reoperation-
free survival in group 1, resulting from the higher SVD
rate (P < .0001, Figure 2, C). A total of 42 patients
(4.2% of the total) were 65 years or younger at surgery.TABLE 1. Freedom from SVD stratified according to age group
Age group (y) Total patients (n) SVD events (n) 5-y Follow
<70 97 10 98.9 (99; n ¼
70-75 343 10 99.4 (99.4; n
76-80 343 3 99.3 (99.4; n
>80 172 1 99.3 (98.4; n
Total 955 24 99.3 (99.4; n
Data presented as actuarial rates, with actual rates given in parentheses, followed by the n
The Journal of Thoracic and CarAmong these, we observed 9 SVD events during the
follow-up period (21.4%).
Figure 3 shows the SVD-free survival at follow-up strat-
ified according to prosthesis size (19 mm vs the remainder)
and postoperative average gradient (<25 vs>25 mm Hg).
No significant intergroup differences were found. The-up 10-y Follow-up 15-y Follow-up P value
81) 93.3 (94.9; n ¼ 44) 58.8 (75.5; n ¼ 5) .04
¼ 280) 98.1 (98.5; n ¼ 150) 88.5 (95.2; n ¼ 13) .37
¼ 259) 98.9 (99.1; n ¼ 116) 98.9 (99.1; n ¼ 13) .98
¼ 131) 99.3 (99.4; n ¼ 34) 99.3 (99.4; n ¼ 3) Reference
¼ 751) 97.9 (98.5; n ¼ 344) 86.3 (95.1; n ¼ 34)
umber of patients at risk at each point. SVD, Structural valve deterioration.
diovascular Surgery c Volume 147, Number 6 1887
TABLE 2. Freedom from reoperation for SVD stratified according to age group
Age group (y) Total patients (n) Reoperation events (n) 5-y Follow-up 10-y Follow-up 15-y Follow-up
<70 97 6 98.9 (99; n ¼ 81) 94.8 (96.1; n ¼ 44) 77.1 (86.1; n ¼ 5)
70-75 343 2 100 (100; n ¼ 281) 99.2 (99.4; n ¼ 152) 99.2 (99.4; n ¼ 15)
76-80 343 0 100 (n ¼ 261) 100 (n ¼ 116) 100 (n ¼ 13)
>80 172 0 100 (n ¼ 133) 100 (n ¼ 34) 100 (n ¼ 3)
Total 955 8 99.9 (99.9; n ¼ 756) 99 (99.4; n ¼ 346) 95.5 (98.4; n ¼ 36)
Data presented as actuarial rates, with actual rates given in parentheses, followed by the number of patients at risk at each point. SVD, Structural valve deterioration.
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leaflet tear and calcification in 4 cases, prevalent calcifica-
tion and stenosis in 2, and leaflet tear in 2 cases.
Overall, 143 patients (15%) experienced at least 1 valve-
related adverse event and, therefore met the composite
endpoint. The freedom from the composite endpoint at 5,
10, and 15 years was 91.3%  0.9%, 83%  1.5%, and
71.3%  3.4% using the actuarial method and 91.9% 
0.9%, 86.4%  1.1%, and 82%  1.6% using the actual
method, respectively. No statistically meaningful inter-
group differences were found in terms of survival free
from the composite endpoint (Kaplan-Meier P ¼ .9,
Figure 2, D). We observed 8 cases of NSVD, leading to re-
operation in 1 case. The actual freedom from NSVD at 15
years was 99.1%  0.3%, without significant intergroup
differences (P¼ .3). Of the 66 patients (6.9%) who experi-
enced a thromboembolic event during the follow-up period,
27 died of ischemic stroke (fatality rate, 41%). The overall
freedom from thromboembolic events was 92.7%  0.9%
at 15 years (actual method); no significant intergroup differ-
ence emerged with the time-to-event analysis (P ¼ .6). The
global rate of prosthetic endocarditis was 1.6% (15 events,
leading to reoperation in 2 cases). The actual freedom at 15
years was 98.2%  0.4% and without significant inter-
group difference (P ¼ .8). Finally, the 4 age groups wereFIGURE 3. Kaplan-Meier curves for follow-up survival from structural valve d
ular gradient at discharge. B, Stratified by prosthesis size (19 mm vs the remai
1888 The Journal of Thoracic and Cardiovascular Surcomparable with respect to valve-related mortality during
the follow-up period (P ¼ .8, Figure 4).
DISCUSSION
The Mosaic porcine bioprosthesis was introduced in
1994. It is a third-generation device characterized by glutar-
aldehyde zero-pressure fixation and antimineralization
treatment with a-amino oleic acid. The durability of this
prosthesis in the aortic position has been the subject of pre-
vious investigations, which included a maximum follow-up
of 13 years in multicenter studies.5,9 Surgeons are
challenged daily with the choice of the most appropriate
valvular substitute (either biologic or mechanical) for
individual patients. The anticipated risk of SVD is 1
major determinant of that choice. Therefore, a precise
estimation of the expected SVD risk according to the
preoperative patient characteristics is of paramount
importance. This problem has been previously addressed
for second-generation devices.6 Nonetheless, it has been
suggested that the clinical results at follow-up could be
markedly age-dependent for third-generation device.10
We have presented 99.8%-complete follow-up data for
1007 Mosaic valves implanted during 10 years within 1
institution. The average follow-up duration was 8.5  3.9
years, with a total of 8122.17 patient-years. The assessmenteterioration (log-rank P values shown). A, Stratified by average transvalv-
nder). SVD, Structural valve deterioration.
gery c June 2014
FIGURE 4. Kaplan-Meier curves for follow-up survival, stratified by age
group (log-rank P values shown). Freedom from valve-related mortality.
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limited number of patients attaining this point (n ¼ 32),
although some patients reached 18 years of follow-up.
Nonetheless, previous investigations have based their
longest follow-up analyses on similar and even smaller pa-
tient cohorts.9,10 In the present study, we have reported the
largest follow-up period available to date for this prosthesis.
Our 86.3% actuarial freedom from SVD at 15 years in the
overall population compares well with the 91% actuarial
freedom reported at 12 years by Jamieson and colleagues.5
Our actual analysis yielded a 95.1% freedom from SVD at
15 years. However, our Canadian colleagues reported a
95.9% actual freedom at 12 years for patients aged 60 years
or older at surgery. This finding agrees with the freedom
rates of 99.4% to 95.2% we observed in our eldest strata
(groups 2-4). Among the younger patients (group 1), we
observed a 75.5% actual freedom rate at 15 years versus
80.6% at 12 years reported Jamieson and colleagues.5
The comparison of such data is limited by the different dis-
tribution of patient age in the 2 populations. The presence in
our series of only 29 patients (2.9%) aged 60 years or
younger at surgery thwarted the creation of a dedicated
age stratum. Also, the definition for SVD used in the study
by Jamieson and colleagues5 implied demonstration by
explant reoperation, and the rates of freedom from reopera-
tion for all valve-related causes were given. This could have
led to an underestimation of the rate of SVD compared with
our series, in which SVD was defined by preoperative tests
with or without explant reoperation. We also specified the
freedom from reoperation from SVD only. Only 33% of
the patients who received a diagnosis of SVD in our series
actually underwent reoperation. Another previous seriesThe Journal of Thoracic and Carreported 89% actuarial freedom from SVD at 13 years,
although that study was potentially biased by a limited sam-
ple size and the lack of actual analysis.9 In other studies, the
actuarial SVD freedom rates ranged from 87.1% at 10 years
to 96.6% at 7 years.11,12 We underline the value of coupling
the actuarial and actual methods to address valve-related
outcomes. Because SVD is, in most cases, a nonfatal
adverse event, the predictions using the actuarial method
will be excessively pessimistic for the patient. In fact, death
from other causes will censor the occurrence of SVD and
related reoperation.8 In contrast, the actual rates will consis-
tently clarify the risk of incurring SVD or reoperation dur-
ing the follow-up period for 1 patient of a given age at the
surgical consultation.13,14 This issue notably contributes
to the choice of an adequate valvular substitute. The
importance of the actual (cumulative risk) method
increases with an increasing follow-up period and the re-
sulting accumulation of other non–SVD-related fatal
events.15 Therefore, it is relevant for the present study and
for similar investigations with even longer follow-up
periods.6,16
It has previously been suggested that the rate of pros-
thetic endocarditis with the Mosaic valve during the
follow-up period tends to be increased in younger pa-
tients.10 This concept was not evident in our experience—
the actual freedom from prosthetic endocarditis at 15 years
ranged from 97.6% to 98.9% among the 4 groups, without
statistically significant differences (P ¼ .8). Similarly, no
other valve-related outcome was age-dependent (NSVD
and thromboembolic events), except for SVD and SVD-
related reoperation. Patients younger than 70 years pre-
sented with increased global rates of SVD, but we did not
observe any association between younger age and earlier
presentation of SVD (Table 2), similar to the findings for
second-generation bioprostheses after equivalent follow-
up periods.6,17 Nonetheless, the older average age in the
present series limited the interpretation, owing to the
greater incidence of non–SVD-related lethal events. The
relevant number of SVD events in group 1 should be
attributed to the patients’ longer life expectancy rather
than to accelerated deterioration. Additionally, none of the
patients in groups 3 and 4 who developed SVD underwent
reoperation for this reason, and reoperation was required
in 33% of the overall SVD patients. Furthermore, isolated
aortic valve repeat replacement is considered to have a
lower operative risk than other types of reoperation.18 How-
ever, patients deemed to have excessive reoperative risk
might be candidates for the transcatheter valve-in-valve
procedure, the indications and technique of which are being
increasingly standardized.19,20 Finally, despite the
increased incidence of SVD in group 1, neither the
freedom from any valve-related adverse event (composite
endpoint; Figure 2, D) nor the valve-related mortality
were statistically different among the 4 groups (Figure 3).diovascular Surgery c Volume 147, Number 6 1889
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complication with potentially serious consequences, its ef-
fect on the patients’ final outcome might be limited in the
current era. Additionally, the 15-year actuarial freedom
from SVD we observed (86.3%) was almost identical to
that found by our group for the Carpentier-Edwards SAV
(Edwards LifeSciences, Irvine, Calif) second-generation
bioprosthesis (85.9%).6
Considerable rates of patient–prosthesis mismatch have
been reported for the 19-mm Mosaic prosthesis,21 and an
association between patient–prosthesis mismatch and
SVD has been suggested.22 Although a limited number of
19-mm valves were used in our population (4.8%), no
SVD event was recorded among the patients who received
the 19-mm prosthesis in our series. Although we did not
have enough data regarding the effective orifice area at
discharge, stratified survival analysis for freedom from
SVD indicated no association between SVD and surrogate
markers of patient–prosthesis mismatch. These included
the 19-mm prosthesis21 and an elevated average transvalv-
ular gradient (Figure 3). This result was confirmed by
Cox regression analysis. Chronologic age was confirmed
as the sole preoperative factor to discriminate the adequate
valve substitute for individual patients. The unavailability
of information for the effective orifice area in the entire
data set did not allow systematic analysis of its variation
over time, a limitation of our investigation. The initial
follow-up evidenced that the average transvalvular gradient
remained stable or even decreased from hospital discharge
to 14 months (from 17.4 to 16.1 mmHg for prostheses sized
21 mm, from 14.2 to 13.3 mm Hg for prostheses sized 23
mm, unchanged at 10.9 mm Hg for prostheses sized 25
mm, and from 14 to 10.4 mm Hg for prostheses sized 27
mm).23
As a collateral finding, we observed an overestimation of
operative mortality as calculated by the logistic Euro-
SCORE I (calculated, 8.6%; observed, 5%). The receiver
operating characteristic curve analysis indicated adequate,
but not very good, diagnostic performance of this risk pre-
diction system.24,25 The long-term results achieved through
bioprostheses should contribute to the current debate
regarding the decision making for high-risk patients
affected by severe aortic stenosis.26 The present study was
characterized by the prospective collection of in-hospital
data and the performance of all operations within the
same center, with standardized surgical and clinical proto-
cols. In addition, to the best of our knowledge, this is the
largest existing series of Mosaic aortic prostheses. These el-
ements strengthen the reliability of our conclusions. How-
ever, the paucity of patients younger than 60 years at
surgery was a potential study limitation, and we were un-
able to provide detailed long-term information for this sub-
group. The relatively low number of patients attaining the
15-year follow-up point also should be considered a1890 The Journal of Thoracic and Cardiovascular Surpotential limitation. Additionally, we lacked sufficient in-
formation regarding the anticoagulation status at the throm-
boembolic and hemorrhagic events during the follow-up
period. The present series included patients who had under-
gone concomitant surgery on the mitral valve; this could
theoretically have confounded the assessment of some
aortic valve-related adverse events (ie, thromboembolism).
Nonetheless, the number of these patients was very limited
(1.1%) and predominantly included mitral repair cases.
Concomitant procedures were not an exclusion criterion
in previous series.2,9 As an additional limitation, we
lacked data on the radiologic analysis of the prostheses
explanted for SVD, because this was not a part of our
postexplantation protocols during the study period.
Our data have confirmed the full legitimacy of implanting
a bioprosthesis in patients aged 70 years or older. Patients
younger than 70 years at of implantation had an increased
rate of SVD; nonetheless, the valve-related mortality and
other valve-related adverse events were not age-
dependent. Implantation of a bioprosthesis in patients
younger than 70 years is justified with correct patient infor-
mation. This should be accomplished using data obtained
through the actual method.
The authors are grateful to Mrs Sylvie Marie and Mrs Anne In-
gels for their invaluable support in the collection and analysis of
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